A role of radioprotective agents in cancer therapeutics: a review

Nagalaxmi Velpula, Sridevi Ugrappa, Srikanth Kodangal

Abstract


In the field of medicine or dentistry, cancer is one of the most common causes for death of the individual worldwide, in which oral cancer accounts for about 10% of it. One of the most important treatment modalities for cancer includes radiotherapy. During radiotherapy, exposure of the normal tissue to these ionizing radiations, results in mutagenesis and cell death. Several modalities and clinical approaches have been made to reduce these early and late complications of the radiotherapies and one among them is, by the means of pharmacological agents. Many experimental and clinical studies have given rise to new concepts of chemical and molecular pharmacological agents that could be effective in protection and treatment of radiation damage to surrounding normal tissues.

 

Clinical Significance: To reduce the significant complications in irradiated patients, the clinical implication of these radioprotective agents have emerged as potential drugs and with anti-tumour effect in the radiotherapy of various cancers including oral carcinomas.


Keywords


Chemical modifiers, Radioprotectors, Radiation damage

Full Text:

PDF

References


Greenberg and Glick. Burket’s Oral Medicine. 11th Edition. Hamilton: BC Decker Inc 2008:153-55.

Greenberger JS. Radioprotection in vivo 2009; 23:323-336.

Reddy SP and Haug RH. Oral and Maxillofacial Surgery Clinics of North America, Oral Cancer 2006;18(4):605-614.

Koukourakis MI. Radiation damage and radioprotectants: new concept in the era of molecular medicine. Br. J. Radiol 2012;85(1012):313-30.

Nair CKK, Dillip K et al. Radioprotectors in Radiotherapy. J Radiat. Res 2001;42:21–37.

Scholes G. Radiation effects on DNA: The Silvanus Thomson memorial lecture. Br. J. Radiol 1983;56:221–231.

Pradhan DS, Nair CKK, Sreenivasan A. Radiation injury repair and sensitization of microorganisms. Proc. Ind. Natl. Sci. Acad 1973;39B:516–530.

Dragaric IG and Dragaric ZD. The radiation chemistry of water. Academic Press, New York.1971:256.

Upadhyay SN, Dwarakanath BS et al. Chemical Radioprotectors. Defence Science Journal 2005;55(4):403-425.

Jalal S. Foundation review: Trends in the development of Radioprotective agents. Drug Discovery Today 2007;12:794-805

Weiss JF, Landauer MR. History and development of radiation-protective agents. Int. J. Radiat. Biol 2009; 7(85):539–573.

Citrin D, Cotrim AP, Hyodo F et al. Radioprotectors and Mitigators of Radiation-Induced Normal Tissue Injury. The Oncologist 2010;15:360–371.

Maisin, Bacq JR and Alexander. chemical radioprotection : past present and future. Int. J. Radiat. Biol 1998;73:443–450.

Kleta R. Cyclophosphamide and mercaptoethanesulfonate therapy for minimal lesion glomerulonephritis. Kidney Int 1999;56: 2312–2313.

Khojasteh NH, Zakerinia M, Ramzi H, Haghshenas M. A new regimen of MESNA (2-mercaptoethanesulfonate) effectively prevents cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplant recipients. Transplant. Proc 2000;32:596-600.

Baliga MS and Suresh Rao. Radioprotective potential of Mint: A brief review. Journal of Cancer and Therapeutics 2010;3(6):255-262.

Dumont F, Roux AL and Bischoff P. Radiation countermeasures agents: an update. Expert Opinion.Ther.Patents 2010; 20 (1):73-101.

Koukourakis MI, Flordellis CS, et al. Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis. Clin Cancer Res 1999;5:3970–6.

Kuter DJ. New thrombopoietic growth factors. Clin Lymphoma Myeloma 2009;9:S347–56.

Ainsworth EJ. From endotoxins to newer immunomodulators: survival-promoting effects of microbial polysaccharide complexes in irradiated animals. Pharmacol Ther 1988;39:223-41.

Biaglow JE. The effects of ionizing radiation on mammalian cells. In: Farhataziz Rodgers MAJ. Ed. Radiation chemistry: principles and applications. New York: VCH 1987:527-63.

Brown PE. Mechanism of action of aminothiol radioprotectors. Nature 1967;213:363-4.

Chirigos MA and Patchen ML. Survey of newer biological response modifiers for possible use in radioprotection. Pharmacol Ther 1988;39:243-6.

Eastgate J, Moreb J, Nick HS, Suziki K et al. A role for manganese superoxide dismutase in radioprotection of hematopoietic stem cells by interleukin-1. Blood 1993;81:639-46.

Livesey JC and Reed DJ. Chemical protection against ionizing radiation. Adv. Radiat. Res 1987;13:285–353.

Phillips L, Text book of Radiation Oncology, 2nd edition. pg:54-55.

Landauer MR, McChesney DG and Ledney GD. Synthetic trehalose dicorynomycolate (S-TDCM): behavioral effects and radioprotection. J. Radiat. Res 1997; 38:45–54.

Kalechman Y, Shani A, Albeck M et al. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties. Immunopharmacology 1995; 29:149–158.

Caloglu M, Caloglu VY and Yalta T. Histopathological comparison of L-Carnitine with amifostine for protective efficacy on radiation induced acute small intestinal toxicity. Journal of Cancer Research And Therapeutics 2012;2(8):260-265.

Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. New England Journal of Medicine 2004;351:2590–2598.

Assayed ME. Radioprotective effects of black seed (Nigella sativa) oil against hemopoietic damage and immunosuppression in gamma-irradiated rats. Immunopharmacology and Immunotoxicology 2010;32(2):284–296.

Suman S, Maniar M, et al. Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response. Radiation Oncology 2012;7(6):1-9.

Barakat IAH, Abbas OA, et al. Evaluation of radio protective effects of wheat germ oil in male rats. Journal of American Science 2011;7(2):664-673.

Efferth and Langguth. Transport processes of radiopharmaceuticals and modulators. Radiation Oncology 2011;6(59):1-10.

Mitchell JL, Judd GG, Diveley RR, et al. Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278. Carcinogenesis 1995;16:3063-3068.